Ann: Reformulation project achieves first milestones and on-track, page-2

This is a great announcement. It's happening rather quickly not sure if this is the normal time frame or not.

- MPL may be delivered as a capsule or a hard tablet depending on the route that best meets the company’s commercial objectives

- BRI has identified formulations that can deliver up to six times more drug per capsule. This is very encouraging as it is approaching the company’s target dose of 10 times more drug per capsule. We remain optimistic that this will be achieved with further optimisation.

- PharmAust looks forward to updating shareholders in early October when the next BRI report is due